urvashi seminar 7
TRANSCRIPT
-
8/2/2019 Urvashi Seminar 7
1/29
-
8/2/2019 Urvashi Seminar 7
2/29
DISSEMINATED INTRAVASCULAR COAGULATION
Disseminated intravascular coagulation (DIC) is a syndrome inwhich either the extrinsic or intrinsic or both pathways areactivated to produce multiple fibrin clots in small blood vessels.The resultant reduction of the coagulation factors and plateletsresults in bleeding. This process is accompained by activation offibrinolysis which further accentuates the bleeding tendency. Mostof the DIC syndromes are acute and generalised. It is a complexsystemic thrombohaemorrhagic disorder involving the generationof intravascular fibrin and the consumption of procoagulants andplatelets.
-
8/2/2019 Urvashi Seminar 7
3/29
MECHANISM OF DIC
The various etiological factors activate:
Extrinsic and intrinsic pathways of coagulation whichresult in widespread clotting in small blood vessels.
As the fibrin monomers polymerise in the microvascularsystem, there is platelet entrapment in the thrombusresulting in thrombocytopenia in addition to markedreduction of clotting factors (consumption coagulopathy).
-
8/2/2019 Urvashi Seminar 7
4/29
Fibrinolytic system is activated simultaneously,
resulting in lysis of fibrin, forming split products
fibrin degradation products (FDP) which furtherinhibits clot formation resulting in widespread
bleeding.
Tissue factor pathway inhibitor (TFPI an
anticoagulant mechanism is disabled in DIC.
Protein C+S are anticoagulant proteins. TNF-a and IL-
1 in sepsis incapacitate protein C and further reduced
via consumption.
-
8/2/2019 Urvashi Seminar 7
5/29
DIC develops acutely when sudden exposure of procoagulants occurs .
Compensatory haemostatic mechanisms are quickly overwhelmed. Chronic DICrefelects a compensated state that develops when blood is intermittently
exposed to tissue factor .Compensatory mechanism in liver and bonemarrow are not
overwhelmed andfrequently occurs in solid tumours.
Obstetric complicationsIn these cases, tissue thromboplastin released from placental tissue activate FX
therby initiating the coagulation sequence and widespread intravascular coagulation
.
2. Malignancies
In AML-M3, leukemic promyelocytes liberate tissue thromboplastin leading yo
DIC thus accentuating the bleeding due to thrombocytopenia.
3. Infections
In Gram Negative septicemia, bacteria liberates endotoxins which activate FXII,thus initiating the intrinisc coagulation cascade and finally widespread DIC.
ACUTE DIC VS. CHRONIC DIC
-
8/2/2019 Urvashi Seminar 7
6/29
SECONDARY FIBRINOLYSIS
Following DIC ,fibrinolysis gets activated and FDPs- D- Dimerformed have an inhibitory effect on clot formation. Plasmin formed
inactivates FV, VIII, IX and XI which further inhibit intrinsic
coagulation cascade.
-
8/2/2019 Urvashi Seminar 7
7/29
CLINICAL MANIFESTATIONS OF ACUTE DIC
Abrupt onset of bleeding in the form of ecchymoses, petechiae.
Bleeding from sites of venipuncture.
Gum bleeding, epistaxis and gastrointestinal haemorrhage.
State of shock may develop.
Acute renal failure is not uncommon.
Signs and symptoms of intracranial bleeding and pulmonaryhaemorrhage.
Clinical features of underlying diseases are present.
-
8/2/2019 Urvashi Seminar 7
8/29
LAB FINDINGS IN DIC
Thrombocytopenia because of utilization of platelets inmicrothrombi.
PT , APTT because of fibrinogenand plasmic digestion ofvarious factors.
FDP +, D-Dimer+.
Thrombin time (TT) because of fibrinogen .
Presence of fragmented RBCs in the peripheral smear.
Intravascular haemolysis may occur.
-
8/2/2019 Urvashi Seminar 7
9/29
Diagnosis/Lab Findings
TestPlatelet count
Fibrin degradation product
(FDP)
Factor assayProthrombin time (PT)
Activated PTT
Throbimn time
Fibrinogen
D-dimer
Antithrombin
AbnormalityDecreased
Increased
DecreasedProlonged
Prolonged
Prolonged
Decreased
Increased
Decreased (Otto,2001)
-
8/2/2019 Urvashi Seminar 7
10/29
Principle of test for presence of
FDPD-Dimer
Latex particles are coated with specific
antibodies to purified FDP.
Serum / Plasma of the plasma is taken and latex
particles (coated with Ab) are added.
Presence of agglutination suggests the presence
of FDP (D-Dimer).
D-Dimer test is specific in diagnosing DIC.
-
8/2/2019 Urvashi Seminar 7
11/29
Detection of fibrinogen/fibrin Degradation products using a
latex aggultination.
Principle:-
A suspension of latex particles is sentisized with specific antibodies to the purifiedFDP fragments D and E. The suspension is mixed on a glass slide with a dilution of
a serum to be tested. Agrregation indicated the presence of FDP in the sample. By
testing different dilutions of the unknown sample, a semiquantitative assay can be
performed.
Reagents :-
Venous blood.
Collected into a special tube (provided with the kit) containing the antifibrinolytic
agent and thrombin.
Test kit.(Oxoid Ltd.)
Positive and negative controls.
Provided by the manufacturer.
Glycine buffer.
-
8/2/2019 Urvashi Seminar 7
12/29
Make 1 in 5 and 1 in 20 dilution of aerum in glycine buffer.
Mix 1 drop of each serum with 1 drop of latex suspension on a glass slide.
Rock the slide gently for2 minute while looking for macroscopic agglutination.
If a posiyive reaction is observed in the higher dilution, make doubling dilutions
from the 1 in 20 dilution until macroscopic agglutinationcan no longer be seen.
Method :-
Allow the tube with blood to stand at 37C until clot retraction
commences. Then centrifuge the tube and withdraw the serum for
testing. It is important that the fibrinogen in the sample is completely
clotted or this will be detected by the test. This may be a problem in the
presence of heparin or a dysfibrinogenaemia or high levels of FDPs.
Addition of a few drops of 100 u(NIH)/ml thrombin will enhance
clotting in these cases.
-
8/2/2019 Urvashi Seminar 7
13/29
INTERPRETATION
Agglutination with a 1 in 5 dilution of serum indicates a concentration ofFDP in excess of 10 ug/ml;agglutination in a 1 in 20 dilution indicates FDP
in excess of 40 ug/ml.
NORMAL RANGE
Healthy subjects have an FDP concentration of less than 10 ug/ml.
Conditions between 10 and 40 ug/ml are found in a variety of conditionsincluding :
Acute venous thromboembolism
Acute myocardial infarction
Severe pneumonia
After major surgery
High levels are seen in systemic fibrinolysis associated with DIC and
thrombolytic therapy with streptokinase
-
8/2/2019 Urvashi Seminar 7
14/29
SCREENING TESTS FOR FIBRIN
MONOMERS
PRINCIPLE
When thrombin acts on fibrinogen, some of the monomers do not polymerise butgive rise to soluble complexes with plasma fibrinogen and FDP. These complexescan be associated in vitro by ethanol or protamine sulphate.
REAGENTS
PPP (PLATELET POOR PLASMA)From the patient and a control.
POSITIVE CONTROL
This is prepared by adding 0.1 ml of thrombin (0.2 NIH units/ml ) to 0.9 ml ofcontrol plasma and incubating at 37C for 30 minutes.
Fibrin threads formed during theincubation are removed by centrifugation.
PROTAMINE SULPHATE
1% (10g/l)
ETHANOL
50% (v/v) in water
-
8/2/2019 Urvashi Seminar 7
15/29
METHODProtamine sulpate test .
Add 0.05 ml of Protamiine sulphate to 0.5ml of patients plasma and to 0.5ml ofpositive control plasma.
Incubate undisturbed at 37C for 30 minutes.
A positive result is indicated by the formation of a fine fibrin network or fibrinstrands.
The presence of amorphous material only is a negative result.
Ethanol gelation testAdd 0.15 ml of ethanol to 0.5 ml of patients plasma and to 0.5 ml of the positivecontrol plasma at room temperature (c 20C).
After gentle agitation inspect the tubes at 1 minute intervals.
A positive result is the formation of a definite gel within 3 minute.
INTERPRETATION Positive gelatin tests are found in the following scenarios :
The early stages of the acute DIC
After major surgery
Severe inflammatory illness, in particular lobar pneumonia
Liver disease
-
8/2/2019 Urvashi Seminar 7
16/29
DETECTION OF CROSS LINKED
FIBRIN D-Dimers USING A LATEX
AGGLUTINATION METHODPRINCIPLE
The latex agglutination method used to detect crosslinked fibrin D-Dimersis identical to the test previously described to FDP, but in this case
thelatex beads are coated with a monoclonal antibody directed specificallyagainstfibrin D-Dimer in human plasma or serum.
Because there is no reaction with the fibrinogen,the need for serum iseliminated and measurements can be performed on plasma samples.
REAGENTS
Several manufacturers market kits for the measurement of D-Dimers. These usually contain the latex suspension, dilution buffer, and positiveand negative controls.
-
8/2/2019 Urvashi Seminar 7
17/29
METHODThe manufacturers protocol should be followed.
Undiluted plasma is mixed with one drop of latexsuspension on a glass slide and the slide is gently rocked forthe length of time recommended in the kit.
If macroscopic agglutination is observed, dilutions of the
plasma are made until agglutination can no longer be seen.
INTERPRETATION
Agglutination with the undiluted plasma indicates aconcentration of D-Dimers in excess of 200 mg/l.
The D-dimer level can be quantified by multiplying thereciprocal of the highest dilution showing a positive result by200 to give a value in mg/l.
-
8/2/2019 Urvashi Seminar 7
18/29
NORMAL RANGE
Plasma levels in normal subjects are < 200 mg/l.There has been much study of D-dimr assays as a useful way ofexcluding thrombosis, but there is naturally a compromisebetween senstivity and specificity especially when a rapidturnaround time is required.
Lack of an international standard and the poor correlationbetween kits mean that the use of kits for this purpose should bevalidated individually.
Number of kits using ELISA methods for the detection of D-dimer,s are now available that have greater senstivity but are
more cumbersome to perform.Latex test using automated analysers may provide an acceptablecompromise.
These tests have now been incorporated into clinical guidelinesaccording to their sensitivity .
-
8/2/2019 Urvashi Seminar 7
19/29
ASSESSMENT OF
FIBRINOLYTIC SYSTEM
Euglobulin lysis time
Euglobulin fraction contains
plasminogen,plasminogen activators and
fibrinogen.The test is a measurement of fibrinolytic activity.
-
8/2/2019 Urvashi Seminar 7
20/29
MANAGEMENT
Principles of treatment in DIC are:
Prompt treatment of the primary disease.
Heparin therapy.
Platelet transfusions.
Replacement therapy with coagulation factors.
Fresh frozen plasma.
-
8/2/2019 Urvashi Seminar 7
21/29
OTHER COAGULATION
DISORDERSHAEMORRHAGIC DISEASE OF THE NEWBORN
Commonly seen in the economically deprived populations.
Due to vitamin k deficiency in the neonate. Delayed colonization of
the gut affects the synthesis of Vitamin k.Bleeding occurs from umbilical cord stump or melena on 2nd/3rdday after birth.
Intracranial bleeding and large imtramuscular haemorrhages may
occur.PT ,APTT .
There is dramatic response to parenteral Vitamin k therapy.
-
8/2/2019 Urvashi Seminar 7
22/29
LIVER DISEASE Hepatic disease results in deficicncy of factors synthesized in liver likeII, VII,IX and X.
Severs liver disease leads to low levels of FV and fibrinogen also.
These factors are required for both extrinsic and intrinsic pathways andtherefore:
PT- prolonged APTT-prolonged
Gastrointestinal haemorrhageis the common manifestation and occursfrom peptic ulcer, or gastritis.
Spontaneous superficial haemorrhage is the clinical presentation insome cases.
-
8/2/2019 Urvashi Seminar 7
23/29
HOW TO INVESTIGATE A CASE
OF BLEEDING DIATHESIS
The focus in such cases is on :History
Physical examination
Blood counts and physical examination
Platelet count
Coagulation profilePT,APTT, TT, fibrinogen assay and FDPDDimer test
Platelet function tests to rule out functional disorder e.g. von Willebrandsdiaease.
-
8/2/2019 Urvashi Seminar 7
24/29
HISTORYAge of onset of bleeding
Whether bleeding is spontaneous induced or traumatic bleeding
Severity and duratiom of haemorrhage
History of drug intake like aspirin chlorthiazide
Past history of dental extraction ,minor surgery and traumatic bleeding
Menstrual history in females
Family history of bleeding disorder
-
8/2/2019 Urvashi Seminar 7
25/29
EXAMINATIONSite of bleedingskin /mucous membrane/intramuscular
/joint.
Platelet disorder : Petechiae,epistaxis,gingival bleeds+
Coagulation disorder : Haematomas, haemarthrosis,
ecchymosis+ ; bleeding in GIT and genitourinary systemnot uncommon.
-
8/2/2019 Urvashi Seminar 7
26/29
3. BLOOD EXAMINATION
Complete haemogram and peripheral smearexamination to rule out acute leukemia,macrocyticanaemia, aplastic anaemia etc. and other causes ofthrombocytopenia.
4. PLATELET COUNT
If low, all secondary causes of thrombocytopeniashould be ruled out before labelling the case as ITP
acute or chronic. Giant platelets observed in BernardSouliersyndrome.
-
8/2/2019 Urvashi Seminar 7
27/29
5. COAGULATION PROFILE
PT : DIC, Vit k deficiency, obstructive jaundice,oral
anticoagulant therapy to be considered.
APTT : DIC, haemophilia A and B, vWD to be
considered. TT : In DIC and fibrinogen deficiency.
Fibrinogen assay : Fibrinogen is reduced in DIC,
hypo/afibrinogenemia.FDP-D-Dimer : +ve in DIC.
-
8/2/2019 Urvashi Seminar 7
28/29
PLATELET FUNCTION TESTS
Platelet aggregation studies with ADP, collagen,epinephrine and ristocetin to rule out vWD,
storage pool defect and Bernard-Soulier syndrome
should be carried out.
The above tests help in arriving at a diagnosis in
bleeding disorders.
In inherited bleeding disorders, it is necessary to
carry out family studies and also tests for detection
of carriers of haemophilia A/B.
-
8/2/2019 Urvashi Seminar 7
29/29